A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use
Pieter J Carpentier1, Cor A J de Jong, Boukje A G Dijkstra
1Novadic-Kentron, Network for Addiction Treatment Services, Sint-Oedenrode, the Netherlands. pjcarpentier@planet.nl
Aims:
Attention deficit/hyperactivity disorder (ADHD) is common among adult patients with substance use disorders. The benefits of treating ADHD in these patients are uncertain and the prescription of psychostimulants is disputed, because of the risk of abuse. This study examined the short-term effectiveness of methylphenidate treatment for ADHD in adults with substance use disorders.
Design:
Double-blind, placebo-controlled, multiple cross-over (A-B-A-B design) comparative trial of methylphenidate versus placebo.
Setting:
In-patient addiction treatment facility.
Participants:
Twenty-five patients with ADHD who were receiving in-patient treatment for various substance use disorders.
Intervention:
During the course of 8 weeks, each participant completed two phases of placebo and two phases of active medication treatment, in a fixed low-dosage schedule (up to 0.6 mg/kg/day). Abstinence was maintained during the study.
Measurements:
The outcome measure was ADHD symptomatology, as measured with the ADHD rating scale-IV. The results were compared using MANOVA repeated measures.
Findings:
Nineteen of the 25 patients completed the trial. A significant reduction in ADHD symptoms was observed in the first week in both conditions. The positive response to active treatment (nine patients; 36%) was not significantly higher than that to placebo (five patients; 20%).
Conclusions:
In this small pilot study, the effect of low-dose methylphenidate in adult ADHD patients with concomitant substance use disorders is limited. ADHD symptoms in adults were susceptible to a distinct short-term placebo response.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
09:16A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Drug Abuse and Addiction: Pharmacological Phenomena
